Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00406471 · ClinicalTrials.gov registry record · Phase 1
Rubeosis Anti-VEGF (RAVE) Trial for Ischemic Central Retinal Vein Occlusion
A Phase 1 study of Ischemic Central Retinal Vein Occlusion, sponsored by Greater Houston Retina Research.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT00406471: Completed Phase 1 study of Ischemic Central Retinal Vein Occlusion, sponsored by Greater Houston Retina Research.
NCT00406471 is a Phase 1 study of Ischemic Central Retinal Vein Occlusion that has completed, run by Greater Houston Retina Research. The registered enrollment target is 20 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00406471, a Phase 1 study of Ischemic Central Retinal Vein Occlusion, has completed, sponsored by Greater Houston Retina Research.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The RAVE (Rubeosis Anit-VEgf) trial, utilizes monthly intravitreal Ranibizumab (Lucentis) injections for 9 months to see if total VEGF blockade will prevent neovascular glaucoma and eliminate the need for panretinal photocoagulation in patients with ischemic central retinal vein occlusion.
Conditions Studied
Interventions
- DRUG Ranibizumab (Lucentis)
Study Locations (1)
Texas
- Vitreoretinal Consultants - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2005-05 |
| Est. Completion | 2011-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00406471
The ClinicalTrials.gov registry entry for NCT00406471 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower). The listed sponsor is Greater Houston Retina Research, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ischemic Central Retinal Vein Occlusion appearing as the primary indexed condition, and to 1 intervention - of which Ranibizumab (Lucentis) is the first listed.
NCT00406471 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00406471 about?
NCT00406471 is a clinical study titled "Rubeosis Anti-VEGF (RAVE) Trial for Ischemic Central Retinal Vein Occlusion". The RAVE (Rubeosis Anit-VEgf) trial, utilizes monthly intravitreal Ranibizumab (Lucentis) injections for 9 months to see if total VEGF blockade will prevent neovascular glaucoma and eliminate the need for panretinal photocoagulation in patients with ischemic central retinal vein occlusion.
What is the current status of trial NCT00406471?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2005-05. Estimated completion is 2011-01.
What conditions does trial NCT00406471 study?
This clinical trial studies the following conditions: Ischemic Central Retinal Vein Occlusion.
What interventions are being tested in trial NCT00406471?
The interventions under investigation include: Ranibizumab (Lucentis) (DRUG).
Who is sponsoring clinical trial NCT00406471?
This trial is sponsored by Greater Houston Retina Research, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00406471 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.